Screener
Vera Therapeutics VERA Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Vera Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:33 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212143
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 122,042 | 130,212 |
| Stockholders’ equity | ||
| Class A common stock, $0.001 par value; 500,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 71,730,090 and 71,267,429 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 72 | 71 |
| Additional paid-in capital | 1,381,678 | 1,364,529 |
| Accumulated other comprehensive (loss) income | (156) | 786 |
| Accumulated deficit | (881,897) | (760,865) |
| Total stockholders’ equity | 499,697 | 604,521 |
| Total liabilities and stockholders’ equity | $621,739 | $734,733 |
Item 1. Financial Statements
FAQ
- What is Vera Therapeutics's retained earnings?
- Vera Therapeutics (VERA) reported retained earnings of -$881.9M in Q1 2026.
- How has Vera Therapeutics's retained earnings changed year-over-year?
- Vera Therapeutics's retained earnings decreased by 71.9% year-over-year, from -$512.94M to -$881.9M.
- What is the long-term trend for Vera Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), Vera Therapeutics's retained earnings has grown at a 52.8% compound annual growth rate (CAGR), from -$91.45M to -$760.87M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Vera Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude